%0 Journal Article %A AKIRA TAKEUCHI %A TETSUYA OGURI %A YORIKO YAMASHITA %A KAZUKI SONE %A SATOSHI FUKUDA %A OSAMU TAKAKUWA %A TAKEHIRO UEMURA %A KEN MAENO %A KENSUKE FUKUMITSU %A YOSHIHIRO KANEMITSU %A HIROTSUGU OHKUBO %A MASAYA TAKEMURA %A YUTAKA ITO %A AKIO NIIMI %T TTF-1 Expression Predicts the Merit of Additional Antiangiogenic Treatment in Non-squamous Non-small Cell Lung Cancer %D 2018 %R 10.21873/anticanres.12882 %J Anticancer Research %P 5489-5495 %V 38 %N 9 %X Background/Aim: To investigate whether TTF-1 expression predicts a beneficial response of non-squamous non-small-cell lung cancer (NS-NSCLC) patients to bevacizumab. Patients and Methods: We retrospectively screened 118 advanced NS-NSCLC patients who were treated with pemetrexed plus platinum derivatives alone (Bev(−)) or with bevacizumab (Bev(+)), and investigated the relationship between expression of TTF-1 and treatment outcomes. Results: Among the 92 TTF-1-positive patients, clinical outcomes in the Bev(+) group were significantly better than those in the Bev(−) group (response rate, 51.4% vs. 27.3%, p=0.027; median progression-free survival, 216 days vs. 137 days, p=0.012). Overall survival in the Bev(+) group tended to be longer than that in the Bev(−) group. However, the addition of bevacizumab to the standard treatment of 26 TTF-1-negative patients offered no clinical benefit. Conclusion: TTF-1 expression may serve as a predictive marker to identify patients who may benefit from the addition of bevacizumab to platinum doublet therapy. %U https://ar.iiarjournals.org/content/anticanres/38/9/5489.full.pdf